# EDGAR Filing Document

**Accession Number:** 0002019505
**File Stem:** 0001213900-26-056707
**Filing Date:** 2026-5
**Character Count:** 158805
**Document Hash:** 4b9aaa281f545d6d40617a0f0147f437
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-056707.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001213900-26-056707

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 56

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Health In Tech, Inc.
- **CENTRAL INDEX KEY:** 0002019505
- **STANDARD INDUSTRIAL CLASSIFICATION:** INSURANCE AGENTS BROKERS & SERVICES [6411]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42449
- **FILM NUMBER:** 26979707

**BUSINESS ADDRESS:**
- **STREET 1:** 701 S. COLORADO AVE
- **STREET 2:** SUITE 1
- **CITY:** STUART
- **STATE:** FL
- **ZIP:** 34994
- **BUSINESS PHONE:** 888-373-0333

**MAIL ADDRESS:**
- **STREET 1:** 701 S. COLORADO AVE
- **STREET 2:** SUITE 1
- **CITY:** STUART
- **STATE:** FL
- **ZIP:** 34994

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

**FORM 10-Q**

☒ **Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**For the quarterly period ended March 31, 2026**

OR

☐ **Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the transition period from _________to___________

**Commission File Number: 001-42449**

**Health In Tech, Inc.** (Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **87-3545722** |
| (State or other jurisdiction of <br> incorporation or organization) | (I.R.S. Employer <br> Identification No.) |
| **701 S. Colorado Ave, Suite 1<br> Stuart, FL** | **34994** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| **888-373-0333** |
| (Registrant's telephone number, including area code) |

---

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Class A common stock, par value $0.001 per share | HIT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

As of May 13, 2026, there were 53,829,562 shares of Class A common stock and 11,700,000 shares of Class B common stock, each with a par value of $0.001 per share, outstanding.

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
|  | **[PART I. FINANCIAL INFORMATION](#a_020)** | 1 |
| Item 1 | [Financial Statements (unaudited)](#a_021) | 1 |
|  | [Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025](#a_022) | 1 |
|  | [Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025](#a_023) | 2 |
|  | [Condensed Consolidated Statements of Changes in Stockholders' Equity for the three months ended March 31, 2026 and 2025](#a_024) | 3 |
|  | [Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025](#a_025) | 4 |
|  | [Notes to Condensed Consolidated Financial Statements](#a_026) | 5 |
| Item 2 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_027) | 24 |
| Item 3 | [Quantitative and Qualitative Disclosures About Market Risk](#a_028) | 37 |
| Item 4 | [Controls and Procedures](#a_029) | 37 |
|  | **[PART II. OTHER INFORMATION](#a_030)** | 38 |
| Item 1 | [Legal Proceedings](#a_031) | 38 |
| Item 1A | [Risk Factors](#a_032) | 38 |
| Item 2 | [Unregistered Sales of Equity Securities and Use of Proceeds](#a_033) | 38 |
| Item 3 | [Defaults Upon Senior Securities](#a_034) | 38 |
| Item 4 | [Mine Safety Disclosures](#a_035) | 38 |
| Item 5 | [Other Information](#a_036) | 38 |
| Item 6 | [Exhibits](#a_037) | 39 |
| [Signatures](#a_038) | [Signatures](#a_038) | 40 |

---

i

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This quarterly report, including, without limitation, statements under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations," includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "potential," "projects," "predicts," "continue," or "should," or, in each case, their negative or other variations or comparable terminology.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (the "SEC"). It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

● our financial performance;

● our ability to obtain funding for our operations, including funding necessary to enhance our current systems as well as the development of additional functionalities of our systems and to expand our service offerings;

● the success, cost and timing of our system offering development activities;

● our ability to attract and retain key personnel;

● our ability to hire and retain necessary qualified employees to expand our operations;

● our ability to attract new customers to utilize our platforms;

● our ability to develop new and enhance products and services to attract and retain customers, and to successfully monetize them;

ii

● the impact of competition in our industry and innovation by our competitors;

● risks related to cybersecurity incidents or other network disruptions;

● risks related to the use of third-party artificial intelligence;

● our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business, including with respect to the insurance services industry and data privacy requirements;

● our ability to protect our intellectual property rights and maintain and build our brand;

● the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology;

● the future trading prices of our Class A common stock; and

● potential claims relating to our intellectual property.

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q. You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or revised expectations.

Because some of these risks and uncertainties cannot be predicted or quantified and may be beyond our control, you should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

This Quarterly Report on Form 10-Q contains estimates, projections and other information concerning our industry, our business and the markets for our products and services. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.

iii

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements.** 

**Health In Tech, Inc.**

**Condensed Consolidated Balance Sheets**

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| **<u>Assets</u>** | | |
| **Current assets** | | |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $10325208 | $7669754 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 3737647 | 756288 |
| &nbsp;&nbsp;&nbsp;Loans receivable, net | 831994 | 815995 |
| &nbsp;&nbsp;&nbsp;Other receivables, net | 4328448 | 3467814 |
| &nbsp;&nbsp;&nbsp;Deferred offering costs |  | 170977 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 2864557 | 3280148 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 22087854 | 16160976 |
| **Non-current assets** |  |  |
| &nbsp;&nbsp;&nbsp;Software | 6708561 | 6530894 |
| &nbsp;&nbsp;&nbsp;Operating lease – right of use assets | 122328 | 139940 |
| &nbsp;&nbsp;&nbsp;Long-term prepaid expenses | 47464 | 258151 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-current assets | 6878353 | 6928985 |
| **Total assets** | $28966207 | $23089961 |
| &nbsp;&nbsp;&nbsp;**<u>Liabilities and stockholders' equity</u>** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $6968261 | $4188811 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities – current | 78680 | 76195 |
| &nbsp;&nbsp;&nbsp;Other current liabilities |  | 891598 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 7046941 | 5156604 |
| **Non-current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Deferred tax liabilities | 273203 | 757675 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities – non-current | 42915 | 63617 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-current liabilities | 316118 | 821292 |
| **Total liabilities** | 7363059 | 5977896 |
| **Commitments and contingencies (Note 5)** |  |  |
| **Stockholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized, 53,858,276 and 46,006,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 53858 | 46006 |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 11700 | 11700 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 17905633 | 11834121 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 3631957 | 5220238 |
| **Total stockholders' equity** | 21603148 | 17112065 |
| **Total liabilities and stockholders' equity** | $28966207 | $23089961 |

---

*The accompanying notes are an integral part of these (unaudited) condensed consolidated financial statements.*

**Health In Tech, Inc.**

**Condensed Consolidated Statements of Operations**

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| **Revenues** |  |  |
| &nbsp;&nbsp;&nbsp;Revenues from underwriting modeling (ICE) | $1468814 | $2351984 |
| &nbsp;&nbsp;&nbsp;Revenues from fees (SMR) | 7302832 | 5663000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenues** | 8771646 | 8014984 |
| **Cost of revenues** | 4262247 | 2659585 |
| **Gross profit** | 4509399 | 5355399 |
| **Operating expenses** |  |  |
| &nbsp;&nbsp;&nbsp;Sales and marketing expenses | 2291601 | 1090255 |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 3455558 | 3246765 |
| &nbsp;&nbsp;&nbsp;Research and development expenses | 920395 | 537721 |
| **Total operating expenses** | 6667554 | 4874741 |
| **Other income:** |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 67471 | 85366 |
| &nbsp;&nbsp;&nbsp;Other income | 22334 | 118399 |
| **Total other income, net** | 89805 | 203765 |
| **Income (loss) before income taxes** | $(2068350) | $684423 |
| &nbsp;&nbsp;&nbsp;Income tax benefit (expense) | 480069 | (185831) |
| **Net income (loss)** | $(1588281) | $498592 |
| Net income (loss) per share: |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $(0.03) | $0.01 |
| &nbsp;&nbsp;&nbsp;Diluted | $(0.03) | $0.01 |
| Weighted average common stock outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 57353021 | 54619858 |
| &nbsp;&nbsp;&nbsp;Diluted | 57353021 | 56996936 |

---

*The accompanying notes are an integral part of these (unaudited) condensed consolidated financial statements.*

 

**Health In Tech, Inc.**

**Condensed Consolidated Statements of Changes in Stockholders' Equity**

**For the Three Months Ended March 31, 2026 and 2025**

(Unaudited)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Class A** | **Class A** | **Class B** | **Class B** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Retained**<br>**Earnings** | **Total**<br>**Stockholders'**<br>**Equity** |
| **Balance as of December 31, 2025** | 46006000 | $46006 | 11700000 | $11700 | $11834121 | $5220238 | $17112065 |
| Issuance of common stock in connection with private investment in public equity financing, net of offering costs and placement agent fees | 5600000 | 5600 |  |  | 5922520 |  | 5928120 |
| Stock-based compensation | 2252276 | 2252 |  |  | 148992 |  | 151244 |
| Net loss |  |  |  |  |  | (1588281) | (1588281) |
| **Balance as of March 31, 2026** | 53858276 | $53858 | 11700000 | $11700 | $17905633 | $3631957 | $21603148 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Class A** | **Class A** | **Class B** | **Class B** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Retained**<br>**Earnings** | **Total**<br>**Stockholders'**<br>**Equity** |
| **Balance as of December 31, 2024** | 42914870 | $42915 | 11700000 | $11700 | $9173017 | $3941396 | $13169028 |
| Stock-based compensation | 58334 | 58 |  |  | 493113 |  | 493171 |
| Net income |  |  |  |  |  | 498592 | 498592 |
| **Balance as of March 31, 2025** | 42973204 | $42973 | 11700000 | $11700 | $9666130 | $4439988 | $14160791 |

---

*The accompanying notes are an integral part of these (unaudited) condensed consolidated financial statements.*

**Health In Tech, Inc.**

**Condensed Consolidated Statements of Cash Flows**

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| Net income (loss) | $(1588281) | $498592 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Amortization expense | 403467 | 135983 |
| &nbsp;&nbsp;&nbsp;Provision for refund liability | 108402 | 780045 |
| &nbsp;&nbsp;&nbsp;Deferred tax benefit | (484472) | (34473) |
| &nbsp;&nbsp;&nbsp;Interest income | (15999) | (15999) |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 366562 | 493171 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (2981360) | (463498) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other receivables | (11740) | (3489536) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 447597 | (1017751) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets and liabilities, net | (605) | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 1437182 | 3420497 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable |  | 220303 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | (1000000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) operating activities** | **(3319247)** | **527353** |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| Development of software | (362131) | (703475) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | **(362131)** | **(703475)** |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| Proceeds from issuance of common stock in connection with private investment in public equity financing, net of placement agent fees and escrow agent fees | 6381000 |  |
| Payments of deferred offering costs | (44168) | (98089) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) financing activities** | **6336832** | **(98089)** |
| Increase (decrease) in cash and cash equivalents | 2655454 | (274211) |
| Cash and cash equivalents, beginning of period | 7669754 | 7849248 |
| Cash and cash equivalents, end of period | $10325208 | $7575037 |
| **Supplemental disclosures of cash flow information:** |  |  |
| Cash paid for interest | $— | $— |
| Cash received from income tax refunds | $4965 | $— |
| **Summary of noncash investing and financing activities:** |  |  |
| Accrued deferred offering costs included in accounts payable and accrued expenses | $237734 | $33250 |
| Accrued development of software included in accounts payable and accrued expenses | $228518 | $256140 |
| Reclassification of deferred offering costs to additional paid-in capital upon private investment in public equity financing | $452880 | $— |
| Stock-based compensation capitalized for software development | $8837 | $— |

---

 

*The accompanying notes are an integral part of these (unaudited) condensed consolidated financial statements*

 

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

(Unaudited)

**1. Organization**

 ****

***Description of Business***

Health in Tech, Inc. (collectively with SMR, Hi Card, and ICE (defined below), "HIT" or the "Company") through its subsidiaries, simplifies sales, service processes and reduces sales cycle time for third-party administrators and brokers. HIT was incorporated in November 2021 in the State of Nevada, and is based in Stuart, Florida. The Company was created with the intention of consolidating each of three standalone entities into a single organization: Stone Mountain Risk, LLC ("SMR"), Health Intelligence Card, LLC ("Hi Card"), and International Captive Exchange, LLC ("ICE") (the "subsidiaries").

The Company's unaudited condensed consolidated financial statements include the accounts of HIT and its wholly owned subsidiaries.

***Private Investment in Public Equity Financing***

On March 27, 2026, the Company completed a private investment in public equity financing (the "PIPE") in which it issued and sold 5,600,000 shares of Class A common stock, $0.001 par value per share ("Class A Common Stock"), at a price of $1.25 per share. The Company received net proceeds of $6,381,000 after deducting placement agent fees and escrow agent fees of $619,000.

***Offering Costs***

 ****

Offering costs of $1,071,880, consisting of legal, accounting, placement agent fees and other costs relating to the PIPE, were offset against the proceeds received upon the closing of the PIPE when recorded in additional paid in capital on the condensed consolidated balance sheets. As of December 31, 2025, $170,977 of offering costs were deferred and recorded on the condensed consolidated balance sheets.

**2. Summary of Significant Accounting Policies**

 ****

***Basis of Presentation***

The Company's unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial information. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2025.

The condensed consolidated balance sheet as of December 31, 2025 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP.

The accompanying condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year ending December 31, 2026.

 ****

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

***Segments***

The Company's chief operating decision maker ("CODM"), the Chief Executive Officer and executive committee, manages the Company's business activities as a single operating and reportable segment from continuing operations at the consolidated level. Accordingly, the CODM uses consolidated net income to measure segment profit or loss, allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (cost of revenues, sales and marketing, research and development, and general and administrative expenses) at the consolidated level to manage the Company's operations. As of March 31, 2026 and December 31, 2025, the Company did not have a material balance of long-lived assets located outside of the United States.

 ****

***Use of Estimates***

The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. Significant items subject to such estimates and assumptions include, but are not limited to, accounts receivable allowance for revenue billing changes driven by headcount changes during the billable period, allowance for credit losses, useful lives of software, variable consideration of revenues from underwriting modeling and stock-based compensation expense. It is at least reasonably possible that the estimates of the effect of conditions, situations or sets of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimates, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. ****

***Cash and Cash Equivalents***

Cash and cash equivalents consist of demand deposit with original maturities less than three months, which are unrestricted as to withdrawal or use.

 ****

***Concentration of Credit Risk***

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable and loans receivable for financial periods ended March 31, 2026 and December 31, 2025. The Company further manages its credit risk on liquid funds through diversification of investment type and credit exposures. For cash, the Company places cash deposits with large financial institutions. For accounts receivable, the credit risk is managed through the use of mitigating controls, including the use of credit checks and credit limits on customers. For loans receivable, the Company monitors the exposures and counterparty credit risk on a regular basis.

 ****

***Concentration of customers***

 

*Revenues from Stop-Loss Insurance Carriers*

For the three months ended March 31, 2026 and 2025, one stop-loss insurance carrier ("Carrier A") individually represented greater than 10% of Company's total gross revenues. Revenue from Carrier A accounted for 17.9% and 25.5% of the Company's total gross revenues for the three months ended March 31, 2026 and 2025, respectively. The amount due from Carrier A was approximately 28.0% and 36.3% of accounts receivable as of March 31, 2026 and 2025, respectively. While the Company is working to cooperate with more stop-loss insurance carriers, it may experience temporary service disruptions in the event the Company deems it necessary to cease use of a stop-loss insurance carrier.

 

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

*Revenues from Business Employer Customers*

The Company does not have significant concentration of revenues from any of its business employer customers. The Company has a diversified customer base and did not have any business employer that accounted for more than 2.0% or 1.5% of the Company's total gross revenues for the three months ended March 31, 2026 and 2025, respectively. No business employers accounted for more than 4.5% or 3.0% of accounts receivable, net as of March 31, 2026 and 2025, respectively.

***Concentration of Cost of Revenues Service Providers***

For the three months ended March 31, 2026, the Company's three primary service providers represented 36.2%, 15.1% and 12.0% of the Company's cost of revenues, respectively. As of March 31, 2026, these three primary service providers accounted for 42.3%, 2.8% and 8.5% of accounts payable balance, respectively. For the three months ended March 31, 2025, the Company's three primary service providers (including one data service provider, disclosed in "*Concentration of Data Service Providers from Third Party Artificial Intelligence Providers*") represented 77.2%, 6.8% and 5.4% of the Company's cost of revenues, respectively. As of March 31, 2025, these three primary service providers accounted for 74.8%, 0.0% and 0.0% of accounts payable balance, respectively. The Company, if necessary, could utilize others as part of its service offerings with a limited impact on the Company's operations.

***Concentration of Data Service Providers from Third Party Artificial Intelligence Providers***

The Company currently utilizes one third-party Artificial Intelligence ("AI") data service provider. For the three months ended March 31, 2026, this provider accounted for 4.2% of the Company's cost of revenues. As of March 31, 2026, this provider accounted for 2.8% of accounts payable balance. For the three months ended March 31, 2025, the Company's two AI providers as of that date represented 6.8% and 0.6% of the Company's cost of revenues, respectively. As of March 31, 2025, no balance was due to these two AI providers. The Company previously utilized two AI data services companies, as pricing was more advantageous than utilizing other vendors within this sector. While the Company has historically utilized these AI data service companies, the Company believes that, if necessary, it could utilize others as part of its service offerings with a limited impact on the Company's operations.

***Leases***

The Company accounts for its leases under the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") ASC 842, Leases ("ASC 842").

The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company recognizes right-of-use assets and lease liabilities that represent the net present value of future lease payments utilizing a discount rate corresponding to the Company's incremental borrowing rate and amortizing over the remaining terms of the leases, which was determined to be 10% during the three months ended March 31, 2026 and 2025. The Company accounts for the leases of less than twelve months as short-term leases and does not recognize right-of-use assets and corresponding lease liabilities. During the year ended December 31, 2025, the Company entered into a 12-month short-term lease agreement with a monthly fixed rent payable, commencing in December of 2025. The Company had one lease classified as short-term leases as of December 31, 2025. During the three months ended March 31, 2026, the Company terminated the short-term lease agreement. The Company had no leases classified as short-term leases as of March 31, 2026.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

***Accounts Receivable and Allowance for Credit Losses and for Revenue Billing Adjustments***

Accounts receivable are carried at original invoice amount, less any estimate made for doubtful accounts or credit losses. In accordance with ASC 326, *Financial Instruments — Credit Losses*, the allowance for credit losses is the Company's best estimate of the amount of expected credit losses in the Company's existing receivables over the contractual term. The Company evaluates its exposure to credit loss on both a collective and individual basis. The Company evaluates such receivables on an individual customer basis and takes into account any relevant available information, which begins with historical credit loss experience and consideration of current and expected conditions and market trends (such as general economic conditions, other microeconomic and macroeconomic considerations, etc.) and reasonable and supportable forecasts that could impact the collectability of such receivables over the contractual term individually or in the aggregate. Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. The allowance for credit losses was $0 as of March 31, 2026 and December 31, 2025, respectively.

The Company also makes the allowance for revenue billing adjustments, under the consideration of the revenues associated with enrolled customers would have changed during the 12-month contractual term. The final reconciliation with the customers is on the 14<sup>th</sup> month. During the year ended December 31, 2025, the Company's monthly revenue provision was 1.3% of total revenues. The provision for customers ending their 12-month plan as of December 31, 2025 without completion of reconciliation was $143,251. The total provision amounted to $634,982 or 1.7% of total revenues for the year ended December 31, 2025. The balance of accounts receivable allowance for revenue billing adjustments related to current year enrollment adjustment was $287,651 as of December 31, 2025. In the first quarter of 2026, the Company was in the process of reconciliation for customer policies that ended as of December 31, 2025. The balance of accounts receivable allowance for revenue billing adjustments related to prior year enrollment adjustment was $132,341 as of March 31, 2026. Starting from January 2026, the Company's monthly revenue provision was 1.7% of total revenues, which was based on the full review of 2025 revenue adjustments. The balance of accounts receivable allowance for revenue billing adjustments related to current year enrollment adjustment was $91,548 as of March 31, 2026. This incorporates three separate categories:

● There is a revenue adjustment that is driven by enrollment changes. It is based upon the actual individuals enrolled in a plan throughout the term compared to the initial employees enrolled in the first month.

● There is a revenue adjustment that is determined at the cancellation of a policy due to delayed payment. Specifically, a Carrier may cancel a plan when the customer does not remit payment in accordance with the respective agreement for a certain period of time (approximately three months). This may be adjusted if there is a slight delay in the completion and execution of required legal documents.

● There is a revenue adjustment and change triggered by re-underwrite of stop loss insurance policy, as defined by the Carrier's underwriting guideline.

***Other Receivables***

Certain business customers elect to receive a discount on premiums payable to carriers. In return, carriers can collect and retain these customers' positive claim fund balance amounts. The positive claim fund is maintained in a designated account specifically earmarked for claims, held by the employer, known as "Deferred Administrative Surplus." As the platform company, the Company tracks and processes claims for carriers. With necessary information for collection available on our platform, the Company signed an agreement on December 28, 2023 with the third-party Roscommon Captive Management and Roscommon Insurance Company (collectively the "Carrier"), to purchase the rights, title, interest, and collection rights to fees totaling $3,100,000 in Deferred Administrative Surplus for $1,650,000, which is 53% of the total collection rights (the "2023 Purchase"). Additionally, the Company entered into a separate agreement with the Carrier on March 18, 2025, to purchase the final batch of Deferred Administrative Surplus totaling $17,408,421 for $3,481,684, which is 20% of the total collection rights (the "2025 Purchase"). Subsequent to the purchase, following the final review and net of inactive insurance policies, the face value of the 2025 Purchase was approximately $13.8 million. This final batch includes stop-loss insurance policies unexpired as of the date of the 2025 Purchase ("active policies"), which were not present in the 2023 Purchase.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

When entering into a stop-loss insurance policy, a business employer can elect to purchase discounted stop-loss insurance policies premiums from the Carrier by agreeing to return any positive balance in claim fund. These claim funds are held in the name of the business employer, and the Carrier has no claim to these funds until the policy and the policy run-out period ends, which is 18 months following commencement of the policy term (the "Policy End Date"). The "run-out period" refers to six month period after the policy or plan has expired during which claims can still be submitted and processed. After the Policy End Date, any funds remaining in the claim fund belong to the Carrier. The Carrier will provide the business employers with a reconciliation of what amounts are specifically owed. This is based on the amount of funds in the business employers' claim fund account, and the value of claims incurred during the policy and run-out period (the "Deferred Administrative Surplus"). The Deferred Administrative Surplus is owned by the Carrier and not subject any contingencies other than the ability to collect from the business employer.

As part of the Company's services to the Carrier, ICE contracted with the Carrier to collect premium and process claims expense. Therefore, in its internal system, the Company can calculate the approximate amount of positive balance in the claims fund. The exact amount will be determined after full reconciliation of the claims fund after completion of the run-out period.

In the case of the 2023 Purchase, the Company purchased the policies with related run-out periods that had lapsed and had positive claim fund balances according to the Company's internal system. As such, the Company knows the value of the Deferred Administrative Surplus purchased. The 2025 Purchase includes all the remaining policies with deferred administrative surplus as a product feature from the Carrier. Collectively, the Carrier and HIT platform stopped offering this feature in August 2024. Thus, 2025 purchased policies are in different periods and stages, including in the policy coverage period, in the run-out period and the out of run-out periods. For policies in the coverage period and in the run-out periods, the final Deferred Administrative Surplus cannot be determined until the policy completes the run-out period and finalizes the reconciliation. Following the purchase, the Deferred Administrative Surplus was transferred to the Company for collection. After the transfer, the Company performs the relevant reconciliations to demonstrate to the business employers the amount of the Deferred Administrative Surplus now owed to the Company from the claim fund balance. The Company asks the business owners to pay back the Deferred Administrative Surplus within 30 days of the collection requests sent.

The key risks associated with the collection of the Deferred Administrative Surplus relate to the Company's limited collections experience related to the Deferred Administrative Surplus at the time of purchase from the Carrier. To reduce the Company's collection risk, the Company negotiated with the Carrier to purchase the Deferred Administrative Surplus at 53% the estimated face value of the 2023 Purchase and 20% of estimated face value of 2025 Purchase. This was due to the Carrier does not have the sufficient resources and procedures to collect the Deferred Administrative Surplus. Moreover, the 2025 Purchase was the final batch of policies with the Deferred Administrative Surplus. The Company would have to collect less than 53% of the Deferred Administrative Surplus balance for the 2023 Purchase to incur a loss, and less than 20% for the 2025 Purchase to incur a loss. As of March 31, 2026, the Company collected $1,272,413 for the 2023 Purchase and $290,282 for the 2025 Purchase. The lower collection amount related to the 2025 Purchase is a result of a substantial majority of the underlying policies remaining in the reconciliation process of the Deferred Administrative Surplus, for which the Company initiates collection requests to business employers only upon the completion of such reconciliations.

The purchase of the Deferred Administrative Surplus does not represent a purchase of a financial asset with credit deterioration as defined in accordance with ASC 326, *Financial Instruments — Credit Losses*. Furthermore, the Company only has approximately three months of historical collection success rates at the time of entering into the 2023 Purchase contract. These collection success rates are based upon limited experience given the Company has only collected on these types of assets for a short period of time. Moreover, the historical collection success rates for the 2023 Purchase were not applicable for the 2025 Purchase at contract inception, due to the differing components of the two purchases, such as active policies in the 2025 Purchase. As such, the Company has accounted for these assets under a nonaccrual approach. The Company will continue to assess this policy as additional collection information is received and collection trends are identified. The Company recorded the consideration as other receivables both as of March 31, 2026 and as of December 31, 2025. The Company collected $12,224 and $0 under the Deferred Administrative Surplus during the three months ended March 31, 2026 and 2025, respectively. Payments made for purchases and collections from the Deferred Administrative Surplus are included in the "other receivables" line of operating activities in the Company's Condensed Consolidated Statements of Cash Flows.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

The Company separately assessed if an allowance for credit losses was necessary for this Other Receivables. The Company assesses its historical credit loss experience and consideration of current and expected conditions and market trends (such as general economic conditions, other microeconomic and macroeconomic considerations, etc.) and reasonable and supportable forecasts that could impact the collectability of such receivables over the contractual term individually or in the aggregate. Other Receivables are written off after all collection attempts have been exhausted. Credit loss expense recognized on Deferred Administrative Surplus, which is presented in Other expense in the Company's Condensed Consolidated Statements of Operations, was $0 for the three months ended March 31, 2026 and 2025.

 ****

***Loans Receivable, Net***

On October 10, 2023, the Company entered into a Promissory Note Agreement with Kang Youle Limited, which constitutes an unsecured lending arrangement. Under this Promissory Note Agreement, the Company agreed to lend $800,000 in principal amount, which bears 8% interest per annum. The note's maturity date is October 10, 2026. The Company has assessed this receivable for potential credit losses, noting none as of March 31, 2026 and December 31, 2025, respectively. The Company recorded this loan receivable at amortized cost on the condensed consolidated balance sheets. See Note 3.

 ****

***Software Capitalization***

The Company incurs certain costs associated with the development of its Hi-Card, eDIYBS systems and other systems. In accordance with ASC 350-40, *Intangibles — Goodwill and Other: Internal-Use Software*, the Company capitalizes certain costs associated with the development of its internal-use software after the preliminary project stage is complete and until the design, coding, installation, and testing of the software have been completed. Upgrades and enhancements are capitalized if they will result in added functionality. Capitalized costs are amortized over an expected three-year period. In May of 2023, the Company determined that its eDIYBS system was ready for its intended use. In September 2025, an expansion of the eDIYBS system was also completed and placed into service. As such, the Company has entered the eDIYBS system in the post-implementation phase. For the three months ended March 31, 2026 and 2025, the Company has amortized $403,467 and $135,983 of the capitalized costs associated with eDIYBS and other systems respectively, which is included in the cost of revenues line item of the Company's Condensed Consolidated Statements of Operations. During the three months ended March 31, 2026 and 2025, the Company capitalized $581,134 and $909,615, respectively, of software development costs.

 ****

***Impairment of Long Lived Assets***

In accordance with ASC 360, *Property, Plant, and Equipment*, the Company evaluates the recoverability of amortizable long-lived assets whenever events or changes in circumstances indicate the carrying value of such asset may not be recoverable. Should there be an indication of impairment, the Company tests recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. There were no impairment losses recognized on long-lived assets during the three months ended March 31, 2026 and 2025.

***Revenue Recognition***

The objective of ASC 606, *Revenue from Contracts with customers* ("ASC 606") is to establish the principles that an entity shall apply to report useful information to users of the financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. An entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, as defined in ASC 606-10-10-1 and ASC 606-10-10-2.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

This evaluation under ASC 606 follows a five-step model, including:

---

| | |
|:---|:---|
| Step 1: | Identify the contract(s) with a customer |
| Step 2: | Identify the performance obligations in the contract |
| Step 3: | Determine the transaction price |
| Step 4: | Allocate the transaction price to the performance obligations in the contract |
| Step 5: | Recognize revenue when (or as) the entity satisfies a performance obligation |

---

In general, ASC 606's core principle is to recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Required disclosures under ASC 606 include qualitative and quantitative information about contracts with customers and significant judgments and estimates as to the application of the 5-step revenue recognition analysis, among others.

The Company accounts for its revenue under the accounting guidance of ASC 606. The Company's contracts that are within the scope of ASC 606 specifically relate to the services that are associated with customers who purchase self-funded benefits plans. These plans are facilitated through a network of brokers, TPAs, MGUs, carriers, and other third-party agents.

 

*Identification of the Performance Obligations*

The Company analyzes each of the deliverables pursuant to its contracts with customers. For each of the deliverables, the Company performs a detailed analysis to determine whether the deliverables are separately identifiable. The Company notes that although the deliverables can vary from day to day, all specifically relate to one kind of service, representing one performance obligation that is provided by each of its subsidiaries (SMR and ICE), as further described below.

 

*SMR Specific Considerations*

 

*Program and Platform Management Services (Legacy)*

Under SMR's Program and platform management services, the Company's insurance marketplace allows brokers to customize an employer's self-funded benefits plan and stop loss insurance policies. When licensed brokers log in to the Company's platform, they upload an employee census representing the employee base of the business employer, select which network they wish to use, what plan designs they want to offer to the business employer and then quickly obtain a bindable self-funded medically underwritten stop loss quote they can provide to their business customers. The chosen vendors provide benefit services as outlined on the platform. The fees that the Company and others charge for the service offerings within the quote are outlined and expressly agreed to by the employer. The employer customizes their health insurance plan and executes an annual agreement. This agreement includes a sold case breakdown (SCB) that outlines the individual stop loss insurance and benefits service offerings selected by the employer and the cost of each, including any optional services offered by the Company or other vendors. Through this, the Company is aware of the services that the broker is offering to the employer for the health insurance plan period, which is normally twelve (12) months. This includes each of the performance obligations provided by its subsidiaries as further outlined below. Subsequent to the execution of the initial bindable SCB with its customers, the Company may modify the health insurance plan during the plan period when a non qualified event occurs based on the definition provided by the carriers. For example, if there is a significant fluctuation or changes of enrolled employees (EEs) from the first month.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

The Company has business relationships with licensed brokers, as licensed brokers register on the Company's platform to select and sell benefits plans and stop loss polices to employers as discussed above. However, there is no contractual relationship between the Company or any of its subsidiaries and the brokers. The Company's platform provides credentialing for licensed brokers, allowing them to access its marketplace to select and sell self-funded benefits plans for the business employer at no cost. Brokers are paid by the businesses, with no contractual relationship between the Company and the brokers, only a credentialing process, and free access is provided.

TPAs are contracted and authorized by the business employers to enter into service contracts with SMR on behalf of the business employers. ASC 606 defines a customer as a party that has contracted with an entity to obtain goods or services that are an output of the ordinary activities of the company in exchange for consideration. SMR is not providing services to the TPAs, but instead, has contracts to collaborate with the TPAs to facilitate the administration of health benefit plans and stop-loss insurance policies to its customers, which are the business employers. The TPA will administer the purchased health benefits plan and manage the multiple service providers associated with the health benefits plan and stop-loss insurance policy. Such service providers are listed on the bindable quotes via the bindable sold case breakdown, which outlines the individual stop loss insurance and benefits service offerings selected by the business and the cost of each. Only the business employer can start or terminate the relationship with SMR. The TPA cannot start or terminate the relationship with SMR. As such, the Company has concluded that the TPAs are not customers and that the business employers are the customers of SMR pursuant to ASC 606.

Effective January 1, 2026, the Company has pivoted its services to offer pre-designed self-funded plans to employers, leveraging years of experience in selecting and managing the vendors that are essential to the plan.

*Self-funded Plan Administration Services (Effective January 1, 2026)*

SMR develops pre-configured, self-funded health benefit plans that integrate full administrative services and then are bundled with stop-loss insurance for employer clients. SMR delivers a comprehensive, end-to-end self-funded health plan solution spanning plan design and ongoing administration.

SMR curates and onboards a network of specialized administrative vendors, contracting directly and tailoring service configurations based on deep operational experience and sector expertise. This enables consistent execution while maintaining flexibility to meet the specific needs of employers and distribution partners.

As of March 31, 2026, SMR includes more than 100 pre-designed plans that can be efficiently configured and bundled with stop-loss coverage, significantly streamlining implementation.

This model simplifies the complexity of self-funded plan administration, materially improves operational efficiency, and provides a differentiated, flexible solution for both employers and sales agents.

*ICE Specific Considerations*

ICE has contractual relationships with carriers. ICE underwrites a stop-loss insurance policy and processes claims per the respective carrier's underwriting guideline and claims processing guideline. In these instances, the carrier is the Company's customer.

The Company's performance obligations related to its revenue can be summarized as follows:

<u>Underwriting modeling and risk services:</u> As a part of the Company's overall insurance marketplace, ICE provides underwriting modelling, machine learning-driven underwriting services, and risk services to its customers. Through its web-based SaaS quoting platform, eDIYBS (Enhance Do It Yourself Benefit System), brokers log in to eDIYBS, upload census, select plans and generate bindable quotes. eDIYBS medically underwrites each employer. ICE continues to assess risks and may re-underwrite based on underwriting risk guidelines provided by carriers. Any enrollment changes in a business can have large fluctuations during a policy period that may trigger a re-underwrite. ICE not only monitors and manages these activities but also facilitates insurance reporting. Revenue related to these services are included in the "Revenues from underwriting modeling" within the Condensed Consolidated Statements of Operations. These services are provided by ICE for carriers. Unlike the Company's other performance obligations, the Company's agreements for its underwriting modeling and risk performance obligations are with stop loss carriers. Under these agreements, the Company develops and maintains all underwriting models, designs risk criteria, assesses the risk to underwrite a policy, monitors claims activities, provides reinsurance reporting, and provides monthly reinsurance filings. The purpose of these services is to ensure that the stop loss carrier is assuming an appropriate amount of risk when taking on a new insurance policy, and further that the premiums being charged are appropriate based upon the population of the new insurance policy (age, demographic, etc.).

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

<u>Program and platform management services:</u> As a part of the Company's overall insurance marketplace, SMR is a program manager specializing in customized self-funded benefits programs for businesses. SMR's expertise in health benefits enables the Company to analyze, review and select vendors that have sufficient experience, which is an essential component of a health plan that is constantly evolving with its business employers based on factors such as employee headcount and a specific employee's geographic location. SMR will then design health plans, select networks, manage vendors, and ultimately construct the benefits plans for the business employers. Licensed brokers log in to the marketplace to select and sell self-funded benefits plans to businesses. The Company throughout the contract period is actively working with the TPA to assist administration of the plan specifically due to headcount changes. SMR also serves as the total program manager coordinate between the Carrier, the TPA, the Broker, and the business employer, the Company's customer. The Company's service offerings encompass reference-based pricing, group insurance captives, community health plans, and association health programs. This service is performed for employers to ensure that they have access to a customized health benefits program. Throughout the term of the policy, SMR is ensuring all covered employees meet the requirements and guidelines of carriers to ensure such employees of the business employer remain covered under the respective insurance policy. For these Program and Platform Management Services, the Company acts as a facilitator and does not control the underlying services prior to transfer to customers. The Company accounts for these services under ASC 606-10-25-14(b) as a series of distinct services that are substantially the same per enrolled employee and have the same pattern of transfer as the delivery of the specified services is satisfied over time, and each service is substantially the same and has the same measure of progress. Revenue related to these services are included in the "Revenues from fees" within the Condensed Consolidated Statements of Operations.

<u>Self-funded plan administration services:</u> SMR delivers a comprehensive, end-to-end self-funded health plan solution to business employers, spanning plan design and ongoing administration. SMR establishes independent pricing for services, and acts as the primary party responsible for service fulfillment. The Company acts as the principal under ASC 606 for these Plan administration services, as it controls the services prior to transfer to employers and is primarily responsible for fulfillment. These services are accounted for under ASC 606-10-25-14(b) as a series of distinct services that are substantially the same per enrolled employee and have the same pattern of transfer. Revenue related to these services are included in the "Revenues from fees" within the Condensed Consolidated Statements of Operations.

Each of the services above allows for the customers to simultaneously receive and consume the benefits of the Company's performance as it performs. Services provided by SMR (either program and platform management or self-funded plan administration) and underwriting activities provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined.

As such, the Company has determined that it is appropriate to recognize revenue over a period of the defined contractual term. The Company has determined that the pattern of transfer of control to the customers is commensurate with its right to invoice given the fact that at the end of each reporting period, all performance obligations of the Company have been satisfied and provided to the Company's customers, and as such, the Company records its revenue based on the sold policy enrollment.

Payments required throughout the duration of the policy start once a policy has become effective, and are subsequently due on policy effective date of the month through the duration of the policy. Given the Company's policy terms, there are no performance obligations that remain unperformed at the end of each reporting period.

 

*Disaggregation of Revenue*

A summary of the Company's disaggregated revenues are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| **Revenues:** |  |  |
| Revenues from underwriting modeling (ICE) | $1577216 | $2630455 |
| Revenues from fees (SMR) | 7239069 | 6302872 |
| &nbsp;&nbsp;&nbsp;Program and platform management fees | 2729889 | 6302872 |
| &nbsp;&nbsp;&nbsp;Self-funded plan administration fees | 4509180 |  |
| Subtotal | 8816285 | 8933327 |
| Contra revenue for billing adjustments | 63763 | (138298) |
| Contra revenue for refund liability | (108402) | (780045) |
| **Total revenues** | $8771646 | $8014984 |

---

 

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

 

*Variable Consideration*

With the exception of its business relationship with one particular carrier, the Company does not have variable consideration that would require constraint from the transaction price of its contracts with customers as the Company receives monthly payments either based on a fixed percentage of the monthly premiums paid by the carrier, or a fixed dollar amount based on the end users serviced during a given month.

For this particular carrier with which the Company's business relationship had otherwise ended in 2024, the Company has an agreement that includes an unprecedented clause allowing for a potential adjustment to be evaluated in May 2026 based on evaluations to be provided by the carrier at the end of the reconciliation stage 24<sup>th</sup> month (the "Adjustment"). The agreement period consists of three stages: (i) the policy in-effect stage, covering the first 12 months from each policy effective date month (August 2023 to May 2025); (ii) the run-out stage, a six month period from the end of the policy term, covering the 13th to 18th months from each policy effective date month (August 2024 to November 2025); and (iii) the reconciliation stage, covering the 19th to 24th months from each policy effective date month (February 2025 to May 2026). The agreement covers stop-loss policies with 11 consecutive policy effective date months, and each policy is subject to all three stages. The Adjustment is assessed based on the carrier's portfolio evaluation at the end of the reconciliation stage in May 2026. This Adjustment represents variable consideration under ASC 606.

For the year ended December 31, 2024, as all policies sold had not reached the end of the run-out stage and based on historical data, approximately 50% to 70% of claims expenses are processed within the six-month run-out stage, the Company concluded that it was probable that there was no significant Adjustment for the period.

In February 2025, the stop-loss policies with the first effective date month ended their run-out stage and entered the reconciliation stage. The Company commenced internal assessments by policy effective date month and began including the Adjustment in the transaction price. This decision was based on updated information from the first stop-loss policies that had completed their six-month run-out stage. The Company has reasonable data to make preliminary estimates of the Adjustment by policy effective date month in lieu of the carrier's evaluation is at portfolio level.

For the three months ended March 31, 2026 and 2025, the Company estimated contra revenue of $108,402 and $780,045, respectively, related to the Adjustment. These amounts reduced revenue from underwriting modeling services provided to the carrier. As of March 31, 2026 and December 31, 2025, refund liabilities of $0 and $891,598 related to the Adjustment were recorded in other current liabilities, respectively. As of March 31, 2026, the Company made interim payments of $4,000,000 to the carrier in connection with the Adjustment, subject to final reconciliation. The Company retains the right to recover any overpaid amounts. The final amount is expected to be finalized upon the carrier's evaluation and verification in May 2026, at which time a final true-up will occur. The Company will update its estimate quarterly to reflect ongoing changes in circumstances until finalization.

*Contract Assets and Contract Liabilities*

Contract assets represent the Company's right to consideration in exchange for goods or services that the entity has transferred to a customer when that right is conditioned on something other than the passage of time. Contract liabilities represent the Company's obligation to transfer goods or services to a customer for which the entity has received consideration. As of March 31, 2026 and December 31, 2025, the Company did not have contract assets or liabilities.

*Costs to Obtain a Contract*

Under ASC 340-40, Other Assets and Deferred Costs — Contracts with Customers ("ASC 340") incremental costs of obtaining a contract, such as sales commissions and bonus programs afforded to brokers, are capitalized if they are expected to be recovered. The Company elected the practical expedient under ASC 340 to expense the costs to obtain a contract as incurred when the expected amortization period is one year or less. As of March 31, 2026 and December 31, 2025, there were no such capitalized costs. All eligible contract acquisition costs expensed by the Company have been included in sales and marketing expenses on the Company's Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025.

 

*Significant Financing Components*

The Company elected the practical expedient that allows the Company to not assess a contract for a significant financing component if the period between the customer's payment and the transfer of the goods or services is one year or less. There was no significant financing components during the three months ended March 31, 2026 and 2025, respectively.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

***Cost of Revenues***

The Company's cost of revenues primarily consists of (i) infrastructure costs to operate its platform, such as hosting fees, fees paid to various third-party partners for access to their technology and services, and amortization expenses of the Company's capitalized internal-use software related to its platform, (ii) costs of plan administrative services provided by the TPA designated in each pre-designed plan and other vendors assigned to each TPA, and (iii) costs related to the captive management activities. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that the risk associated with the Company's service offerings is minimized.

***Stock-Based Compensation Expense***

 ****

In accordance with ASC 718, *Compensation — Stock Compensation*, the Company's share-based compensation program grant awards include stock options, restricted stock awards ("RSAs") and unrestricted stocks to officers, employees, directors and non-employees. The fair value of stock options granted in July 2023 and August 2024 was determined using the Binomial option-pricing model. The fair value of RSAs granted before the Company's initial public offering (the "initial public offering" or the "IPO") was based on the fair value of the Company's common stock on the date of the grant, using the DCF method and back-solve method, respectively. The fair value of unrestricted and restricted stocks granted after the IPO is based on the closing market price on the date of the grant.

The Company grants stock options and RSAs that are subject to either service or service and performance-based vesting conditions. Compensation expense for awards to officers, employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate awards' forfeitures and records stock-based compensation expense only for those awards that are expected to vest. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for services, which is generally over the vesting period of the award. Should the Company terminate any of its consulting agreements, the unvested options and RSAs underlying the agreements would be cancelled. Compensation expense for awards to officers, employees, directors and non-employees with service and performance-based vesting conditions is recognized based on the grant-date fair value over the requisite service period on a straight-line basis to the extent achievement of the performance condition is probable. The Company reassesses the probability of achieving the performance condition at each reporting date and begins recognizing expense only when it is probable that the condition will be met.

The Company's expected stock price volatility assumption is based on the volatility of comparable public companies. The expected term of a stock option granted to employees and directors (including non-employee directors) is based on the average of the contractual term (generally 5 years) and the vesting period. For non-employee options, the expected term is the contractual term. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the life of the option. The expected dividend yield was set to zero as the Company does not pay dividends on its common stock and there was no expectation of doing so as of the respective grant dates.

***Net Income (Loss) Per Share***

Net income (loss) per share is provided in accordance with ASC 260, *Earnings per Share*. The Company computes basic net income (loss) per share by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The Company's Class A Common Stock and Class B common stock, $0.001 par value per share ("Class B Common Stock" and together with the Class A Common Stock, "common stock"), have identical dividend and liquidation rights and are therefore considered a single class for purposes of calculating earnings per share.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

Diluted net income (loss) per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive, including unvested RSAs and outstanding stock options. For the purpose of computing diluted net income (loss) per share, RSAs and options with a performance-based vesting condition are considered contingently issuable, and such contingent shares are included in the denominator for computing diluted net income (loss) per share only once the performance condition is met, and only to the extent such RSAs and options are dilutive. For the three months ended March 31, 2026, no diluted shares attributable to RSAs and options were included in the calculation of net loss per share. For the three months ended March 31, 2025, diluted shares attributable to 510,563 RSAs and 1,866,515 options were included in the calculation of net income per share.

The following table sets forth the computation of basic and diluted net income (loss) per share of common stock for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| Net income (loss) | $(1588281) | $498592 |
| Weighted average shares outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 57353021 | 54619858 |
| &nbsp;&nbsp;&nbsp;Total dilutive effect of outstanding equity awards |  | 2377078 |
| &nbsp;&nbsp;&nbsp;Diluted | 57353021 | 56996936 |
| Net income (loss) per share |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $(0.03) | $0.01 |
| &nbsp;&nbsp;&nbsp;Diluted | $(0.03) | $0.01 |

---

The following outstanding stock awards were not considered in the computation of diluted net income (loss) per share attributable to holders of common stock as they had antidilutive effects for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| Restricted stock awards | 2873437 |  |
| Option awards | 1924825 |  |
| **Total** | 4798262 |  |

---

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**2. Summary of Significant Accounting Policies** (cont.)

***Recently Issued Accounting Standards Not Yet Adopted***

In November 2024, the FASB issued *ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.* This standard calls for enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026, with the option to apply it retrospectively. Early adoption is allowed. Currently, the Company is assessing the potential impact of this guidance on its condensed consolidated financial statement disclosures.

In September 2025, the FASB issued ASU 2025-06 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which amends certain aspects of the accounting for and disclosure of software costs under ASC 350-40. The new standard is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is allowed. The new standard may be applied prospectively, retrospectively, or via a modified prospective transition method. Currently, the Company is assessing the potential impact of this guidance on its condensed consolidated financial statement disclosures.

 ****

**3. Loans Receivable, Net**

On October 10, 2023, the Company entered into a Promissory Note Agreement with Kang Youle Limited, which constitutes an unsecured lending arrangement. Under this Promissory Note Agreement, the Company agreed to lend $800,000 in principal amount, which bears 8% interest per annum. The note's maturity date is October 10, 2026. As of March 31, 2026 and December 31, 2025, the outstanding principal amount was $800,000. The Company accrued interest that is due and receivable in the amount of $31,994 and $15,995 as of March 31, 2026 and December 31, 2025, respectively. This amount is included within "Loans receivable, net" on the condensed consolidated balance sheets.

Although not part of HIT's core business, the Company will strategically invest its assets in a manner to maximize risk-adjusted return and promote shareholder wealth. The Company provided the promissory note to Kang Youle Limited, an independent third party with access to a network of insurance sectors internationally.

**4. Stockholders' Equity**

The Company has three classes of stock: (1) Class A Common Stock; (2) Class B Common Stock, and (3) Series A Preferred Stock.

The total number of shares of stock that the Company has authority to issue is 220,000,000, consisting of 150,000,000 shares of Class A Common Stock, 50,000,000 shares of Class B Common Stock and 20,000,000 shares of Series A Preferred Stock, $0.001 par value per share ("Series A Preferred Stock").

Holders of Class B Common Stock are entitled to ten votes per share while holders of Class A Common Stock are entitled to one vote per share. Both classes of common stock vote collectively with the holders of Series A Preferred Stock. Each share of Series A Preferred Stock is entitled to one vote. In addition, the affirmative vote of a majority of the outstanding Series A Preferred Stock is required to approve certain fundamental corporate actions, including mergers, liquidations, the issuance of senior or parity equity securities, and any amendments to the Company's governing documents that would adversely affect the rights of holders of Series A Preferred Stock.

Holders of Class A Common Stock and Class B Common Stock are entitled to dividends when, and if, declared at the discretion of the Company. However, holders of Series A Preferred Stock are entitled to receive non-cumulative dividends prior and in priority to any dividends declared on the common stock. Accordingly, no dividends may be paid on common stock unless all declared dividends on the Series A Preferred Stock have been paid or set aside for payment.

On March 27, 2026, the Company completed a PIPE financing through which it issued and sold 5,600,000 shares of Class A Common Stock, at a price of $1.25 per share. The Company received net proceeds of $6,381,000 in the PIPE after deducting placement agent fees and escrow agent fees of $619,000.

From time to time, the Company issues shares of common stock in connection with the granting of RSAs and the exercise of stock options under its equity incentive plans. For a detailed summary of these issuances and related stock-based compensation, please refer to Note 7.

As of March 31, 2026 and December 31, 2025, 53,858,276 and 46,006,000 shares of Class A Common Stock were issued and outstanding, respectively. As of March 31, 2026 and December 31, 2025, 11,700,000 shares of Class B Common Stock were issued and outstanding, respectively. As of March 31, 2026 and December 31, 2025, no shares of Series A Preferred Stock were issued and outstanding.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**5. Commitments and Contingencies**

 ****

***Legal Proceedings***

From time to time, the Company is party to various litigation matters incidental to the conduct of its business. The Company is not presently party to any legal proceedings the resolution of which it believes would have a material adverse effect on its business, prospects, financial condition, liquidity, results of operation, cash flows or capital levels.

***Leases***

The Company entered into a five-year lease for its corporate headquarters in Stuart, Florida, commencing in November of 2022. The Company's real estate lease also includes executory costs such as common area maintenance (non-lease component) and real estate taxes (not considered a component of the Company's lease). As a practical expedient permitted under ASC 842, the Company has elected to account for the lease and non-lease components as a single lease component. The rent-related expense for this lease was $20,812 for both the three months ended March 31, 2026 and 2025. The Company had no short-term leases as of March 31, 2026, and one short-term lease as of December 31, 2025.

The Company's office lease is classified as an operating lease. At the inception date of the office lease, the Company recorded a right-of-use asset of $330,554 in operating lease right-of-use asset, as well as an operating lease liability of $324,021. This lease liability represented the net present value of future lease payments for the lease utilizing a discount rate of 10%, which corresponded to the Company's incremental borrowing rate.

During the three months ended March 31, 2026 and 2025, the Company made cash payments of $21,417 and $20,794 for amounts included in the measurement of lease liabilities, respectively.

The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the Condensed Consolidated Balance Sheet as of March 31, 2026:

---

| | |
|:---|:---|
| 2026 | 64895 |
| 2027 | 66180 |
| Total undiscounted lease liabilities | $131075 |
| Less effects of discounting | (9480) |
| Total lease liabilities | $121595 |

---

The remaining lease term was 1.6 years and 1.8 years as of March 31, 2026 and as of December 31, 2025, respectively.

The discount rate used to determine the operating lease liability was 10% both as of March 31, 2026 and as of December 31, 2025.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**6. Income Taxes**

Income (loss) before income taxes consists of the following:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| Federal | $(2068350) | $684423 |
| Foreign |  |  |
| Income (loss) before income taxes | $(2068350) | $684423 |

---

During the three months ended March 31, 2026 and 2025, the Company recognized an income tax benefit of $480,069 and an income tax expense of $185,831, respectively.

The Company's income tax provision consists of the following for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31** | **Three Months Ended<br> March 31** |
|  | **2026** | **2025** |
| Current income tax expense |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal | $— | $177143 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State | 4403 | 43160 |
| &nbsp;&nbsp;&nbsp;Total current income tax expense | $4403 | $220303 |
| &nbsp;&nbsp;&nbsp;Deferred income tax expense (benefit) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal | (343181) | (39234) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State | (141291) | 4762 |
| &nbsp;&nbsp;&nbsp;Total deferred income tax benefit | $(484472) | $(34472) |
| &nbsp;&nbsp;&nbsp;Total income tax provision | $(480069) | $185831 |

---

Beginning in its 2025 annual financial reporting, the Company adopted ASU 2023-09 on a prospective basis. The following table presents the reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax provision for the three months ended March 31, 2026 after the adoption of ASU 2023-09:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31, 2026** | **Three Months Ended<br> March 31, 2026** |
|  | **Amount** | **Rate** |
| Statutory federal income tax rate | (434354) | 21.0% |
| State taxes (net of federal benefit) | (62492) | 3.0 |
| Permanent difference | 3952 | (0.2) |
| Other | 12825 | (0.6) |
| Effective tax rate | (480069) | 23.2% |

---

The following table presents the reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax provision for the three months ended March 31, 2025 prior the adoption of ASU 2023-09:

---

| | |
|:---|:---|
|  | **Three Months Ended<br> March 31, 2025** |
| Statutory federal income tax rate | 21.0% |
| State taxes (net of federal benefit) | 5.7 |
| Permanent difference | 0.5 |
| Effective tax rate | 27.2% |

---

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**6. Income Taxes** (cont.)

The Company's net deferred tax assets and liabilities consisted of the following as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Deferred tax assets: |  |  |
| &nbsp;&nbsp;&nbsp;Net Operating Loss | 861977 | 388182 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 60253 | 53586 |
| &nbsp;&nbsp;&nbsp;Bad debt allowance | 90806 | 91828 |
| &nbsp;&nbsp;&nbsp;Accrued liability | 8050 | 8140 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross deferred tax assets | $1021086 | $541736 |
| Deferred tax liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Research & Development credits | (1294258) | (1299380) |
| &nbsp;&nbsp;&nbsp;ROU/Lease Liability | (31) | (31) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Deferred Tax Liabilities | $(1294289) | $(1299411) |
| Net deferred tax liabilities: | $(273203) | $(757675) |

---

As of March 31, 2026, the Company had federal net operating loss carryforwards of $3,585,532, which may be carried forward indefinitely to offset future taxable income, but are subject to the 80% taxable income limitation upon utilization. Additionally, the Company had state net operating loss carryforwards of approximately $3.6 million as of March 31, 2026, which will begin to expire in 2045.

In general, under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, a corporation that undergoes an "ownership change" is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards ("NOLs") to offset future taxable income. As of March 31, 2026, the Company has not performed such an analysis evaluation the potential limitation of the Company's net operating loss carryforwards due to the "Change in ownership" as defined under Section 382 of the Internal Revenue Code.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law, introducing significant and wide-ranging changes to the U.S. federal tax system. Significant components include the return to immediate expensing of domestic research and experimental expenditures ("R&E") which in some cases may include retroactive application back to 2021 for businesses with gross receipts of less than $31 million or accelerated tax deductions of R&E that was previously capitalized for larger businesses. The legislation also reinstates EBITDA-based interest deductions for tax purposes and makes several business tax incentives permanent. Less favorable business provisions include limitations on tax deductions for charitable contributions. The OBBBA did not have a material impact on income tax benefit or expense or related tax assets or liabilities, as the Company does not have significant NOLs, interest expense or charitable contributions. The Company has reviewed the various elections available under the OBBBA for the treatment of domestic research and development expenses and plans to expense domestic research and development costs starting in 2025 along with accelerating the amortization of previously capitalized and unamortized research and development costs. The Company will not apply retroactive treatment to any prior tax periods.

The amounts of cash income taxes paid (received) by the Company were as follows:

---

| | |
|:---|:---|
|  | **Three Months Ended<br> March 31, 2026** |
| Federal |  |
| State | (4965) |
| Foreign |  |
| Total | $(4965) |

---

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**7. Stock-Based Compensation**

 ****

***2022 Equity Incentive Plan***

On December 21, 2022, the Company adopted and approved the Health in Tech Equity Incentive Plan (the "2022 Plan"), which provides for the issuance of 4,501,683 shares of Class A Common Stock for purposes of attracting, retaining, and motivating key employees, directors, and consultants. The 2022 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock and restricted stock units. Upon the consummation of the Company's initial public offering on December 24, 2024, the 2024 Equity Incentive Plan (the "2024 Plan") went into effect. The terms of the 2022 Plan continue to govern the restricted stock and options outstanding in the plan as of March 31, 2026 and December 31, 2025. There are no shares reserved for future issuance in the 2022 Plan.

 ****

***2024 Equity Incentive Plan***

On December 24, 2024, the Company adopted and approved the 2024 Plan. The 2024 Plan is a comprehensive incentive compensation plan under which the Company can grant 7,677,849 shares of equity-based and other incentive awards to officers, employees, directors, consultants and advisers. On October 3, 2025, the Company's stockholders approved an amendment to the 2024 Plan to (i) increase the total number of shares of Class A common stock authorized for issuance pursuant to awards granted thereunder from 7,677,849 shares to 10,677,849 shares and (ii) to include the issuance of up to 2,000,000 shares of Class B Common Stock, and options convertible into Class B Common Stock to executive officers of the Company. The purpose of the 2024 Plan is to help the Company attract, motivate and retain such persons with awards under the 2024 Plan and thereby enhance shareholder value. The 2024 Plan provides for the grant of stock options, stock appreciation rights, performance share awards, performance unit awards, distribution equivalent right awards, restricted stock awards, restricted stock unit awards and unrestricted stock awards. Under the 2024 Plan, 1,288,000 shares of unrestricted stock awards and 3,623,744 shares of restricted stock awards were granted as of March 31, 2026. And 1,288,000 shares of unrestricted stock awards and 1,363,744 shares of restricted stock awards were granted as of December 31, 2025.

Some RSAs granted under the 2024 Plan have service-based vesting conditions and vest over a period from one to two years. Some RSAs granted under the 2024 Plan are subject to both service and performance-based vesting conditions. These awards vest upon the achievement of specified metrics. Depending on the award, these metrics are either measured over a concurrent service period, or act as a prerequisite that must be met to initiate a subsequent 12-month service-based vesting schedule, with the awards vesting in equal monthly installments. The assessment for this prerequisite may occur within a fixed period or be indefinite. Compensation expense for awards with service and performance-based vesting conditions is recognized based on the grant-date fair value over the requisite service period on a straight-line basis to the extent achievement of the performance condition is probable. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**7. Stock-Based Compensation** (cont.)

***Restricted Stock Awards***

*Service-based RSAs*

The table below identifies the service-based RSAs activity under the 2024 Plan for the relevant periods presented:

---

| | | |
|:---|:---|:---|
|  | **Numbers of<br> RSAs** | **Weighted<br> Average<br> Fair Value<br> Per RSA** |
| Unvested as of December 31, 2025 | 321060 | $0.92 |
| &nbsp;&nbsp;&nbsp;Granted | 20000 | 1.18 |
| &nbsp;&nbsp;&nbsp;Vested | (53071) | 1.74 |
| &nbsp;&nbsp;&nbsp;Canceled/Forfeited |  |  |
| Unvested as of March 31, 2026 | 287989 | $0.78 |

---

As of March 31, 2026, there was $146,125 of unrecognized compensation cost, adjusted for estimated forfeitures based on historical data, related to non-vested service-based RSAs. The RSAs are expected to be recognized over a weighted-average remaining requisite service period of 0.5 years, using the straight-line method. The total fair value of the RSAs vested was $92,466 and $0 during the three months ended March 31, 2026 and 2025, respectively. The weighted-average grant-date fair value per share of RSAs granted was $1.18 during the three months ended March 31, 2026. No service-based RSAs were granted during the three months ended March 31, 2025.

*Service and performance-based RSAs*

The table below identifies the service and performance-based RSAs activity under the 2022 Plan and 2024 Plan for the relevant periods presented:

---

| | | |
|:---|:---|:---|
|  | **Numbers of<br> RSAs** | **Weighted<br> Average<br> Fair Value<br> Per RSA** |
| Unvested as of December 31, 2025 | 386768 | $2.58 |
| &nbsp;&nbsp;&nbsp;Granted | 2240000 | 1.57 |
| &nbsp;&nbsp;&nbsp;Vested | (33596) | 2.13 |
| &nbsp;&nbsp;&nbsp;Canceled/Forfeited | (7724) | 0.71 |
| Unvested as of March 31, 2026 | 2585448 | $1.71 |

---

As of March 31, 2026, there was $177,387 of unrecognized compensation cost, adjusted for estimated forfeitures based on historical data, related to non-vested service and performance-based RSAs that were considered probable of achievement. The RSAs are expected to be recognized over a weighted-average remaining requisite service period of 0.5 years, using the straight-line method. The total fair value of the RSAs vested was $71,575 and $14,369 during the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, there was $3,891,328 of unrecognized compensation expense related to non-vested service and performance-based RSAs that were considered not probable of achievement. The weighted-average grant-date fair value per share of RSAs granted was $1.57 during the three months ended March 31, 2026. No service and performance-based RSAs were granted during the three months ended March 31, 2025.

**Health In Tech, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**7. Stock-Based Compensation** (cont.)

***Options***

The table below identifies the stock options activity under the 2022 Plan for the relevant periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Outstanding<br> stock options** | **Weighted<br> average<br> exercise<br> price** | **Weighted<br> average<br> remaining<br> contractual<br> life (years)** | **Aggregate<br> intrinsic<br> value** |
| Balance as of December 31, 2025 | 2151947 | $0.76 | 2.4 | $1805713 |
| Granted |  |  |  |  |
| Exercised |  |  |  |  |
| Canceled/Forfeited | (227122) | 1.19 |  |  |
| Balance as of March 31, 2026 | 1924825 | $0.71 | 2.3 | $1424371 |
| Vested as of March 31, 2026 | 1784491 | $0.71 | 2.3 | $1320523 |
| Vested and expected to vest as of March 31, 2026 | 1924825 | $0.71 | 2.3 | $1424371 |

---

The intrinsic value of a stock option is calculated as the difference between the per share exercise price of the underlying stock option award and the closing stock price on the last trading day in fiscal quarter. There were no stock options granted or exercised during the three months ended March 31, 2026 and 2025. The total fair value of options vested during the three months ended March 31, 2026 and 2025 was $14,897 and $18,979, respectively.

As of March 31, 2026, there was $43,396 of unrecognized compensation cost, adjusted for estimated forfeitures based on historical data, related to non-vested service and performance-based stock options, which is expected to be recognized over a weighted-average remaining requisite service period of 0.5 years, using the straight-line method.

**8. Subsequent Events**

On April 10, 2026, the Company made a cash investment of $428,571 in exchange for an 85.7% equity ownership interest in HITChain Inc. ("HITChain"), a private entity formed on January 2, 2026. The remaining 14.3% equity interest in HITChain is held by the Company's Chief Executive Officer and Chief Financial Officer. Prior to this investment, HITChain had no material assets, liabilities, or ongoing operations.

The Company evaluated the transaction under ASC 810 Consolidation and determined that it has a controlling financial interest in HITchain. Accordingly, the Company will consolidate HITchain's financial statements, with the remaining 14.3% ownership interest presented as a noncontrolling interest in equity.

On April 10, 2026, HITChain granted non-qualified stock options to purchase shares of its Class B common stock, $0.001 par value per share, to the Company's Chief Executive Officer and Chief Financial Officer. Each executive received 1,000,000 options with identical terms, including an exercise price of $0.01 per share, 100% vesting on the grant date, and a 10-year term expiring on April 10, 2036. The options are subject to the terms of HITChain's equity incentive plan.

On April 20, 2026, HITChain granted 500,000 restricted shares of its Class A common stock to the Company's Chief AI & Marketing Officer pursuant to HITChain's equity incentive plan. The officer departed from his position with the Company effective April 30, 2026, and commenced providing consulting services to HITChain as an independent contractor as of May 1, 2026. The restricted shares will vest in equal monthly installments over a 12-month period, commencing on the date on which certain performance conditions are satisfied, subject to the grantee's continued service to HITChain through the applicable vesting date.

On April 8, 2026, the Company granted an aggregate of 40,794 RSAs to its three independent directors under the 2024 Plan, with 13,598 RSAs to each independent director. These awards were vested in full on the grant date, subject to the director's requisite service in the first quarter of 2026.

On April 10, 2026, the Company granted one executive officer 5,000 RSAs under the 2024 Plan. These awards will vest in equal monthly installments over a 12-month period, commencing on April 6, 2026, subject to his continued service through each applicable vesting date.

On April 15, 2026, the Company cancelled and retired 60,068 shares of common stock surrendered by three executive officers to satisfy tax withholding obligations in connection with the net settlement of equity awards.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

 

*You should read the following discussion of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. In addition to our historical condensed consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A, "Risk Factors."*

**Overview**

Health In Tech ("HIT") is an insurance technology platform company, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriters (MGUs) and TPAs.

Marketplace: We are a health insurance marketplace where insurance companies can list various stop-loss policy options for self-funded benefits plans. Licensed brokers registered on our platform can log in, upload certain required information, select policy plans, obtain a bindable quote and sell them to businesses. In most cases, our technology enables us to medically underwrite insurance policies and produce bindable quotes within about two minutes for small employers (10-100 employees) and about two weeks for larger employers (exceeding 100 employees), allowing us to deliver an integrated and seamless sales cycle.

Customizable Solutions: Beyond policy underwriting and sales, our marketplace offers customization of health benefits plans, vendors, claims, and network services. Brokers can select customized plans that suit their customers.

Accessibility and Savings: We make self-funded benefits plans and stop loss insurance accessible online for businesses. We aim to deliver meaningful cost savings for low-risk employers with comparatively healthy employees through a digital medical underwriting process. We seek to deliver time savings for employers, brokers, TPAs, and carriers, by leveraging both external and internally developed technology.

As of March 31, 2026, we had 507 business clients in 38 states, with our services and platforms actively utilized by 608 brokers, 11 Third-Party Administrators (TPAs), and 277 additional third-party agencies. In addition, we continued the revenue growth, with revenue up 9% year-over-year in the first quarter of 2026 compared to the same period in 2025.

We currently generate most of our revenue from service fees and underwriting fees, that are associated with customers who purchase self-funded benefits plans and stop loss insurance. These plans are facilitated through a network of brokers, TPAs, MGUs, carriers, and other third-party agents. These agencies either directly engage our services or provide valuable client referrals.

**Recent Developments**

 ****

On March 25, 2026, we entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE"), which closed on March 27, 2026, resulting in gross proceeds of $7.0 million, before deducting placement agent fees and offering expenses. In connection with the closing of the PIPE, we issued an aggregate of 5,600,000 shares of Class A Common Stock at a purchase price of $1.25 per share. We intend to use the net proceeds from the PIPE for sales distribution expansion, technology development, and general corporate purposes.

**Key Factors Affecting our Performance**

 ****

***Our ability to retain and expand our network of brokers, TPAs, MGUs and other third-party agents.***

While we generate our revenue primarily from employers and insurance carriers, we currently derive substantially all of our business through brokers, TPAs, and other third-party agents who provide referrals. As a result, the size of our network is critical to our success. We have experienced significant network growth since we commenced operations, and we believe we have the opportunity to continue to grow our network by providing superior innovation in automation, great client experience, competitive pricing, access to quality providers, and competitive insurance coverage relative to other insurers in the same geographic and insurance markets.

***Our ability to enter into more collaborations with insurance carriers and offer new products and plans***

Our business growth will depend on our ability to collaborate with a diverse range of insurance carriers to service the excess coverage needs of our clients. These collaborations are essential for expanding our portfolio of products and services. Our growth strategy is heavily reliant on our capability to introduce innovative insurance products and plans. By collaborating with multiple insurance carriers, we can leverage their expertise and resources to develop a broader range of offerings. This not only enables us to meet the specific requirements of our clients but also helps in staying competitive in a rapidly changing market.

 ****

***Our ability to accurately perform underwriting procedures***

Our growth is significantly dependent on our ability to accurately perform underwriting procedures and maintain strong relationships with brokers, TPAs, carriers, MGUs, and other third-party agents who utilize our platforms. A failure to conduct precise underwriting actuarial reviews and adjustments to our underwriting tools could result in increased costs and pricing for health plans.

While we are not bound by any agreements that would necessitate paying fees exceeding estimated insurance costs, nor do we have agreements that require indemnification of the carrier, such a failure could cause reputational harm to our eDIYBS platform. This could lead to increased premiums for plans accessed through our platform, potentially affecting our financial standing and market competitiveness.

 ****

***Our ability to continue invest in technology and innovation***

Our ongoing commitment to investing in technology is crucial for driving advancements in automation and enhancing operational efficiency across all aspects of our business. We are dedicated to regularly updating and developing new technology. This continuous investment in technology and innovation will position us at the forefront of the insurance technology.

 ****

 ****

***Seasonality***

Our business is generally affected by the seasonal patterns of our enrollment and medical expenses. Usage of our underwriting and quoting platform is seasonal, primarily due to the common renewal of health plan policies in December and January. While we believe we have visibility into the seasonality of our business, our rapid growth rate over the last couple years may have made seasonal fluctuations more difficult to detect. If our rate of growth slows over time, seasonal or cyclical variations in our operations may become more pronounced, and our business, results of operations and financial position may be adversely affected.

**Key Financial and Operating Performance Metrics**

We regularly monitor a number of financial and operating metrics in order to measure our current performance and project our future performance. These metrics help us develop and refine our growth strategies and make strategic decisions. We discuss revenues, cost of revenues, and the components of operating expenses. We utilize other key metrics as described below.

***Contracted Revenue***

 ****

Contracted revenue represents the aggregate gross dollar value of contractually committed revenue under active policies as of the measurement date that is expected to be recognized in future periods. Our policies are typically written for terms of 12 months, and revenue is recognized ratably over the life of the policy.

As of March 31, 2026, contracted revenue expected to be recognized during the remaining three quarters of 2026 totaled $22.9 million.

Contracted revenue provides visibility into future revenue that has been contractually secured but not yet earned or recognized, and reflects the forward revenue associated with in-force policies. We use this metric to evaluate the predictability of our revenue base and the growth of our business.

Contracted revenue is presented prior to the impact of monthly adjustments, including changes in enrolled participants, plan mix, and other factors that may affect premium and fees. Accordingly, actual revenue recognized in future periods may differ from contracted revenue.

 ****

***Platform Placed Plan Value (PPPV)***

Platform placed plan value represents the aggregate contractual value of self-funded health plans with stop-loss insurance (self-funded stop-loss plans) placed through our platform, covering the duration of the plans' contractual terms. The contractual term is typically 12 months from the plan's effective date.

In the first quarter of 2026, the platform placed $82.0 million of self-funded stop-loss plans. These consist of self-funded health plans and bundled stop-loss premiums.

***Adjusted EBITDA***

Adjusted EBITDA represents our net income (loss) before net interest expense, taxes and amortization expense, adjusted to eliminate stock-based compensation expense, including employer payroll taxes related to stock-based awards. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. Please refer to "Results of Operations*"* in this item for a discussion of the limitations of adjusted EBITDA and reconciliations of adjusted EBITDA to net income (loss), the most comparable GAAP measurements, respectively, for the three months ended March 31, 2026 and 2025. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance.

**Components of Operating Results**

 ****

***Revenues***

While we generate our revenue primarily from employers and insurance carriers, we grow our business primarily from offering solutions that streamline sales processes, enhance service delivery, and reduce the sales cycle.. We offer our services through our subsidiaries. Program and platform management services and self-funded plan administration services provided by SMR and MGU activities provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined. Currently ICE does not offer underwriting services as a standalone service. In the future, we may consider offering standalone service based on different functionalities and technology deliveries.

&nbsp;&nbsp;&nbsp;&nbsp;(i) SMR is a program manager specializing in customized self-funded benefits
 programs and pre-designed bundled plan options for businesses. Under its legacy program and platform management services, it does the
 program, selects networks and adds vendors, and sets up benefits plans on the marketplace after the vendors are selected by the brokers
 for the plan, including benefits structures, coverage options, and provider networks. Licensed brokers log in to the marketplace to select
 and sell self-funded benefits plans for businesses. SMR collaborates with TPAs and licensed brokers to design health plans that meet the
 specific needs of employers. Starting January 1, 2026, SMR has expanded its service scope and launched
 the new self-funded plan administration services, enhancing its service model to deliver pre-configured, end-to-end self-funded health
 benefit solutions. Leveraging long-term vendor management experience, SMR develops a full suite of pre-designed customized plans bundled
 with stop-loss insurance coverage. The distribution partners, mainly brokers for now, are presented with over 100 configured plans. The
 Company curates and directly contracts with a dedicated network of specialized administrative vendors, tailoring service setups to fit
 employer and distribution partner needs with balanced standardization and flexibility. As of March 2026, over 100 configurable pre-designed
 plan options are available, which are rapidly implemented and combined with stop-loss coverage, greatly reducing plan administration complexity
 and driving overall operational efficiency. This enhanced service model provides employers and sales with more streamlined, differentiated
 and flexible self-funded plan arrangements. The revenue from SMR is derived from a set fee charged per enrolled
 employee (EE) per month (PEPM). The fee varies depending on the type of plans selected by the broker or other distribution partner. These
 fees may vary based on plan design, covered population. SMR's fees are part of self-funded stop loss plan payments, paid by employers.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) ICE develops and maintains all underwriting models. It defines risk criteria based on risk guidelines provided by carriers, manages underwriting of risk, manages claims activity, ensures reinsurance reporting, and handles monthly reinsurance filings. The revenue from ICE is derived as a specific percentage from the premium received, in our capacity as the Managing General Underwriter (MGU) of insurance companies (Carriers). ICE's fees are paid by carriers.

The following table sets forth the components of our revenues by subsidiaries and percentages of our total revenues for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **% of <br> revenue** | **2025** | **% of <br> revenue** |
| **Revenues** |  |  |  |  |
| Revenues from underwriting modeling (ICE) | $1468814 | 16.7% | $2351984 | 29.3% |
| Revenues from fees (SMR) | 7302832 | 83.3% | 5663000 | 70.7% |
| **Total revenues** | 8771646 | 100.0% | 8014984 | 100.0% |

---

 ****

***Cost of revenues***

Cost of revenues primarily consists of (i) infrastructure costs to operate our platform, such as hosting fees, fees paid to various third-party partners for access to their technology and services, and amortization expenses of our capitalized internal-use software related to the platform, (ii) costs of plan administrative services provided by the TPA designated in each pre-designed plan and other vendors assigned to each TPA, and (iii) costs related to the captive management activities. We mainly outsource captive management services and data services from the third-party companies. Our internal proprietary system seeks to consistently improve underwriting and services results through machine learning and data feeds. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that our risk associated with our service offerings is minimized. See Part II, *"Item 1A. Risk Factors — Risks Related to our Business and Industry"* for additional information on the risks associated with our service offerings.

 ****

***Sales and marketing expenses***

Sales and marketing expenses primarily consist of (i) costs associated with expanding the our distribution channels through third-party agents, which are variable and based on policies sold and fees collected, and (ii) costs related to the internal sales team responsible for onboarding agencies and agents onto the platform. These expenses include commissions, incentive compensation, salaries and benefits, and other related selling costs. Sales and marketing expenses also include the costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party for sales and customer acquisition.

 ****

***General and administrative expenses***

General and administrative expenses primarily consist of personnel-related costs and related expenses for our executives, finance, legal, human resources, technical support, and administrative personnel as well as the costs associated with professional fees for external legal, accounting, and other consulting services, insurance premiums.

 ****

***Research and development expenses***

Research and development expenses primarily consist of personnel-related costs, including salaries, stock-based compensation expense and benefits for our research and development personnel. Additional expenses include costs related to research, design, and preliminary planning of new technology, as well as routine maintenance of its existing platform.

 ****

***Income Tax Benefit (expense)***

Income tax benefit (expense) consists primarily of changes to our current and deferred federal and state tax assets and liabilities. Deferred income taxes are recognized for the tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Our deferred tax assets and liabilities are calculated by applying the current tax rates and laws to taxable years in which such differences are expected to reverse.

We continually review the need for, and the adequacy of, valuation allowances, and recognize benefits from our deferred tax assets only when an analysis of both positive and negative factors indicates that it is more likely than not such benefits will be realized.

**Results of Operations**

The following table sets forth our condensed consolidated statements of operations for the periods presented, both in absolute amount and as a percentage of our total revenues for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **% of<br> revenue** | **2025** | **% of<br> revenue** |
| **Revenues** |  |  |  |  |
| Revenues from underwriting modeling (ICE) | $1468814 | 16.7% | $2351984 | 29.3% |
| Revenues from fees (SMR) | 7302832 | 83.3% | 5663000 | 70.7% |
| **Total revenues** | 8771646 | 100.0% | 8014984 | 100.0% |
| **Cost of revenues** | 4262247 | 48.6% | 2659585 | 33.2% |
| **Gross profit** | $4509399 | 51.4% | $5355399 | 66.8% |
| **Operating expenses** |  |  |  |  |
| Sales and marketing expenses | 2291601 | 26.1% | 1090255 | 13.6% |
| General and administrative expenses | 3455558 | 39.4% | 3246765 | 40.5% |
| Research and development expenses | 920395 | 10.5% | 537721 | 6.7% |
| **Total operating expenses** | 6667554 | 76.0% | 4874741 | 60.8% |
| **Other income:** |  |  |  |  |
| Interest income | 67471 | 0.8% | 85366 | 1.1% |
| Other income | 22334 | 0.2% | 118399 | 1.5% |
| **Total other income, net** | 89805 | 1.0% | 203765 | 2.6% |
| **Income (loss) before income taxes** | $(2068350) | (23.6)% | $684423 | 8.6% |
| Income tax benefit (expense) | 480069 | 5.5% | (185831) | (2.3)% |
| **Net income (loss)** | $(1588281) | (18.1)% | $498592 | 6.3% |
| **Other Financial Data:** |  |  |  |  |
| Adjusted EBITDA<sup>(1)</sup> | $(1288515) | (14.7)% | $1228211 | 15.3% |

---

(1) We define adjusted EBITDA as net income (loss) before net interest expense, taxes and amortization expense, adjusted to eliminate stock-based compensation expense, including employer payroll taxes related to stock-based awards. See "*Adjusted EBITDA*" below for more information and for a reconciliation of adjusted EBITDA to net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP.

**Adjusted EBITDA**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| **Reconciliation from Net Income (Loss) to Adjusted EBITDA:** |  |  |
| Net income (loss) | $(1588281) | $498592 |
| &nbsp;&nbsp;&nbsp;Interest income | (67471) | (85366) |
| &nbsp;&nbsp;&nbsp;Amortization expense | 403467 | 135983 |
| &nbsp;&nbsp;&nbsp;Income tax expense (benefit) | (480069) | 185831 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense, including employer payroll taxes related to stock-based awards | 443839 | 493171 |
| &nbsp;&nbsp;&nbsp;Total net adjustments | 299766 | 729619 |
| &nbsp;&nbsp;&nbsp;Adjusted EBITDA | $(1288515) | $1228211 |

---

**Condensed Consolidated Balance Sheet Data**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Cash and cash equivalents | $10325208 | $7669754 |
| Accounts receivable, net | 3737647 | 756288 |
| Other receivables, net | 4328448 | 3467814 |
| Software | 6708561 | 6530894 |
| Total assets | 28966207 | 23089961 |
| Total liabilities | 7363059 | 5977896 |
| Total stockholders' equity | 21603148 | 17112065 |

---

***Cash and cash equivalents***

As of March 31, 2026, cash and cash equivalents increased by $2,655,454 to $10,325,208, from $7,669,754 as of December 31, 2025. This increase was mainly attributable to $6,336,832 in net cash provided by financing activities for the three months ended March 31, 2026. On March 27, 2026, we completed a PIPE financing through which we issued 5,600,000 shares of Class A Common Stock. Please refer to "*Liquidity and Capital Resources*" for additional information.

 ****

***Accounts receivable, net***

As of March 31, 2026, the net accounts receivable increased by $2,981,359 to $3,737,647, from $756,288 as of December 31, 2025. This increase was mainly attributable to the launch of SMR's self-funded plan administration service effective January 1, 2026 and the growth in revenues for the three months ended March 31, 2026.

***Other receivables***

As of March 31, 2026, the net other receivables increased by $860,634 to $4,328,448, from $3,467,814 as of December 31, 2025. This increase was mainly attributable to the amounts due from employees in connection with statutory tax withholdings on equity awards, to be settled via net settlement arrangements.

***Software***

As of March 31, 2026, the balance of software increased by $177,667 to $6,708,561, from $6,530,894 as of December 31, 2025. This increase was mainly attributable to a $581,134 investment in software development, partially offset by a $403,467 increase in accumulated amortization for the three months ended March 31, 2026.

 ****

***Total liabilities***

As of March 31, 2026, the balance of total liabilities increased by $1,385,163 to $7,363,059, from $5,977,896 as of December 31, 2025. This increase was mainly attributable to the growth in accounts payable and accrued expenses, primarily consisting of $926,011 due to TPAs in connection with SMR's self-funded plan administration services launched on January 1, 2026, and $581,686 due to distribution partners for the costs associated with expanding the our distribution channels through third-party agents.

***Total stockholders' equity***

As of March 31, 2026, the balance of total stockholders' equity increased by $4,491,083 to $21,603,148, from $17,112,065 as of December 31, 2025. This increase was mainly attributable to our net proceeds of $5,928,120 from our PIPE, after deducting offering costs and placement agent fees. Please refer to our Condensed Consolidated Statements of Changes in Stockholders' Equity for additional information.

**Comparison of Three Months Ended March 31, 2026 and 2025**

***Revenues***

 **

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period Change** | **Period-to-Period Change** |
|  | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage** |
| Revenues from underwriting modeling (ICE) | 1468814 | 16.7% | 2351984 | 29.3% | (883170) | (37.6)% |
| Revenues from fees (SMR) | 7302832 | 83.3% | 5663000 | 70.7% | 1639832 | 29.0% |
| &nbsp;&nbsp;&nbsp;Program and platform management fees | 2850676 | 32.5% | 5663000 | 70.7% | (2812324) | (49.7)% |
| &nbsp;&nbsp;&nbsp;Self-funded plan administration fee | 4452156 | 50.8% |  | —% | 4452156 | NM |
| Total revenues | 8771646 | 100.0% | 8014984 | 100.0% | 756662 | 9.4% |

---

"NM" denotes that the percentage change is not meaningful.

Total revenues for the three months ended March 31, 2026 reached $8.8 million, up 9.4% from $8.0 million in the same period of 2025. This growth was primarily driven by offering pre-designed self-funded plans with end-to-end administrative services.

As the services provided by SMR and ICE are delivered as an interdependent and integrated solution, we evaluate their performance based on the total revenues generated. While revenues from underwriting modeling generated from ICE decreased by $0.9 million to $1.5 million, this decline was more than offset by a $1.6 million increase in revenues from fees generated from SMR, leading to a net increase in the revenues from the integrated solution.

Revenues from fees continue to outpace revenues from underwriting modeling as SMR launched the pre-designed self-funded plan administration services effective on January 1, 2026. SMR enhance its services to offer pre-designed self-funded plans to employers, leveraging years of experience selecting and managing the vendors that are essential to the plan. This new service model provides employers with more streamlined, differentiated and flexible self-funded plan arrangements.

***Cost of revenues***

 ****

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period <br> Change** | **Period-to-Period <br> Change** |
|  | **Amount** | **Percentage of Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** |
| Cost of revenues | 4262247 | 48.6% | 2659585 | 33.2% | 1602662 | 15.4% |

---

Cost of revenues increased by $1.6 million to $4.3 million for the three months ended March 31, 2026, from $2.7 million for the three months ended March 31, 2025. As a percentage of revenue, cost of revenues increased to 48.6% for the three months ended March 31, 2026, from 33.2% for the same period in 2025.

The increase was primarily attributable to costs of plan administrative services provided by the TPA and other vendors assigned to each TPA, as we continued to enhance our services and launched the pre-designed plan offerings in January 2026, which gave rise to the related plan administrative costs.

***Sales and marketing expenses***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period <br> Change** | **Period-to-Period <br> Change** |
|  | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** |
| Sales and marketing expenses | 2291601 | 26.1% | 1090255 | 13.6% | 1201346 | 12.5% |

---

Sales and marketing expenses were $2.3 million for the three months ended March 31, 2026, more than doubled compared to $1.1 million for the three months ended March 31, 2025. As a percentage of revenue, sales and marketing expenses increased to 26.1% for the three months ended March 31, 2026, compared to 13.6% for the same period in 2025, primarily due to the increase in sales distribution fees with agencies, which drives revenue growth without the need for a large in-house sales force.

***General and administrative expenses***

 ****

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period <br> Change** | **Period-to-Period <br> Change** |
|  | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** |
| General and administrative expenses: |  |  |  |  |  |  |
| Operations division | 1248863 | 14.2% | 1231002 | 15.4% | 17861 | (1.2)% |
| Administrative division | 2206695 | 25.2% | 2015763 | 25.1% | 190932 | 0.1% |
| Total General and administrative expenses | 3455558 | 39.4% | 3246765 | 40.5% | 208793 | (1.1)% |

---

We bifurcate general and administrative expenses as follows:

<u>Operations division</u> — The operations division mainly consists of payroll, stock-based compensation expense and benefits expenses incurred related to our underwriting, claims management, operations development, enrollment, nursing and strategic program development personnel.

<u>Administrative division</u> — The administrative division mainly represents payroll, stock-based compensation expense and benefits expenses incurred related to Executives, Human Resources, Accounting, Finance and Legal related personnel.

General and administrative expenses increased by $0.2 million to $3.5 million for the three months ended March 31, 2026, from $3.3 million for the three months ended March 31, 2025. The overall increase in general and administrative expenses was primarily attributable to the increased expenses associated with being a public company, including D&O insurance, board compensation, investor relations, media outreach, etc. As a percentage of revenue, general and administrative expenses decreased to 39.4% for the three months ended March 31, 2026, from 40.5% for the same period in 2025. This decrease was primarily attributable to the improved operating leverage in our operations division, which was partially offset by increased expenses associated with being a public company.

***Research and development expenses***

 ****

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period <br> Change** | **Period-to-Period <br> Change** |
|  | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** |
| Research and development expenses | 920395 | 10.5% | 537721 | 6.7% | 382674 | 3.8% |

---

Research and development expenses increased by $0.4 million to $0.9 million for the three months ended March 31, 2026, from $0.5 million for the three months ended March 31, 2025. As a percentage of revenue, research and development expenses increased to 10.5% for the three months ended March 31, 2026, from 6.7% for the same period in 2025.

The personnel-related costs associated with capitalized software development decreased by $0.3 million to $0.2 million for the three months ended March 31, 2026, from $0.5 million for the same period in 2025. The decrease was primarily attributable to the changes in the composition of development projects. During the three months ended March 31, 2026, our IT remained focused on developing new functionalities and features for our next-generation platform.

 ****

***Income before income taxes***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period <br> Change** | **Period-to-Period <br> Change** |
|  | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** |
| Income (loss) before income taxes | (2068350) | (23.6)% | 684423 | 8.6% | (2752773) | (32.2)% |

---

Income before income taxes decreased by $2.8 million to a loss of $2.1 million for the three months ended March 31, 2026, from income of $0.7 million for the three months ended March 31, 2025. This decrease was primarily attributable to the plan administrative service costs and distribution fees, which were not incurred in the same period in 2025.

***Income tax benefit (expense)***

 ****

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period<br> Change** | **Period-to-Period<br> Change** |
|  | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** |
| Income tax benefit (expense) | 480069 | 5.5% | (185831) | (2.3)% | 665900 | 7.8% |

---

Provision for income taxes decreased by $0.7 million to an income tax benefit of $0.5 million for the three months ended March 31, 2026, from an income tax expense of $0.2 million for the three months ended March 31, 2025. The decrease in provision for income taxes was primarily attributable to the loss before income taxes, driven by the plan administrative service costs and distribution fees, which were not incurred in the same period in 2025. **

 ****

***Adjusted EBITDA***

 **

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2026** | **2025** | **2025** | **Period-to-Period<br> Change** | **Period-to-Period<br> Change** |
|  | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** | **Amount** | **Percentage of <br> Revenue** |
| Adjusted EBITDA | (1288515) | (14.7)% | 1228211 | 15.3% | (2516726) | (30.0)% |

---

Adjusted EBITDA decreased by $2.5 million to negative $1.3 million for the three months ended March 31, 2026, from $1.2 million for the three months ended March 31, 2025. As a percentage of revenue, adjusted EBITDA decreased to negative 14.7% for the three months ended March 31, 2026, from 15.3% for the same period in 2025. The decrease in adjusted EBITDA was primarily attributable to the plan administrative service costs and distribution fees, which were not incurred in the same period in 2025.

**Liquidity and Capital Resources**

 ****

***Sources of Liquidity***

To date, we have funded our operations primarily through cash generated from operating activities, our IPO completed in December 2024, and our PIPE financing completed in March 2026.

Our cash and cash equivalents as of March 31, 2026 were held in order to fund our working capital needs. We do not enter into investments for trading or speculative purposes. Our policy is to invest any cash in excess of our immediate requirements in investments designed to preserve the principal balance and provide liquidity.

Accordingly, our cash and cash equivalents are invested primarily in demand deposit and money market accounts that are currently providing minimal returns. We believe our existing cash reserves, together with cash generated from our operating activities, will allow us to continue as a going concern at least twelve months from the date of this Quarterly Report on Form 10-Q.

***Summary of Cash Flows***

 ****

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| Cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;Operating activities | $(3319247) | $527353 |
| &nbsp;&nbsp;&nbsp;Investing activities | (362131) | (703475) |
| &nbsp;&nbsp;&nbsp;Financing activities | 6336832 | (98089) |
| &nbsp;&nbsp;&nbsp;Increase (Decrease) in cash and cash equivalents | $2655454 | $(274211) |

---

 

*Operating Activities*

Net cash used in operating activities was $3.3 million for the three months ended March 31, 2026, compared to $0.5 million of net cash provided by operating activities for the same period in 2025. This shift was primarily due to the net loss in the three months ended March 31, 2026, compared to net income in the same period in 2025, along with increased working capital requirements. Cash used in operating activities for the three months ended March 31, 2026, principally resulted from net loss of $1.6 million, offset by $0.4 million in adjustments for non-cash items primarily related to amortization, deferred tax benefits and stock-based compensation expense. This also included $2.1 million of cash used to fund changes in working capital, including an increase in accounts receivable of $3.0 million, a decrease in prepaid expenses and other assets of $0.5 million, an increase in accounts payable and accrued expenses of $1.4 million, and a decrease in other current liabilities of $1.0 million.

Cash provided by operating activities for the three months ended March 31, 2025, principally resulted from net income of $0.5 million, $1.3 million in adjustments for non-cash items primarily related to amortization, provision for refund liability and stock-based compensation expense, and offset by $1.3 million of cash used to fund changes in working capital, including an increase in accounts receivable of $0.4 million, an increase in other receivables of $3.5 million, an increase in prepaid expenses and other assets of $1.0 million, an increase in accounts payable and accrued expenses of $3.4 million, and an increase in income taxes payable of $0.2 million.

*Investing Activities*

Cash used in investing activities decreased by $0.3 million to $0.4 million for the three months ended March 31, 2026, compared to $0.7 million for the same period in 2025. The primary use of cash in investing activities for the three months ended March 31, 2026 and 2025 were both related to the development of our proprietary AI-enabled platform, reflecting our continued investment in enhancing our technology platforms.

*Financing Activities*

Net cash provided by financing activities was $6.3 million for the three months ended March 31, 2026, compared to $0.1 million of net cash used in financing activities for the same period in 2025. The increase was primarily attributable to proceeds from the issuance of Class A Common Stock in connection with our PIPE financing. For the three months ended March 31, 2025, the primary use of cash in financing activity was related to the payments of deferred offering cost for our IPO.

**Contractual Obligations and Commitments**

Our principal commitments consist of obligations under our non-cancellable lease for our office. The following table summarizes the contractual obligations as of March 31, 2026. Future events could cause actual payments to differ from these estimates.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Payment due by period** | **Payment due by period** | **Payment due by period** | **Payment due by period** | **Payment due by period** |
|  | **Total** | **Less than <br> 1 year** | **1 – 3 <br> years** | **3 – 5 <br> years** | **More than <br> 5 years** |
| Operating lease obligations | 131075 | 64895 | 66180 |  |  |

---

**Critical Accounting Policies and Estimate** 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. We also have other key accounting policies, none of these policies or estimates are considered critical accounting policies or critical accounting estimates.

**Recent Accounting Pronouncements**

In November 2024, the FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This standard calls for enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026, with the option to apply it retrospectively. Early adoption is allowed. Currently, we are assessing the potential impact of this guidance on our condensed consolidated financial statement disclosures.

In September 2025, the FASB issued ASU 2025-06 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which amends certain aspects of the accounting for and disclosure of software costs under ASC 350-40. The new standard is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is allowed. The new standard may be applied prospectively, retrospectively, or via a modified prospective transition method. Currently, we are assessing the potential impact of this guidance on our condensed consolidated financial statement disclosures.

We do not believe that any other recently issued but not yet effective accounting pronouncements are expected to have a material effect on our condensed consolidated financial statements.

**JOBS Act**

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. We have elected to early adopt certain new accounting standards, as disclosed herein. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Class A Common Stock that is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to emerging growth company will have the meaning associated with it in the JOBS Act.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required by this Item.

**Item 4. Controls and Procedures**

 ****

***Evaluation of Disclosure Controls and Procedures***

Disclosure controls and procedures are controls and other procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to Management, including our Chief Executive Officer and Chief Financial Officer (together, the "Certifying Officers"), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our Management, including our Certifying Officers, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the foregoing, our Certifying Officers concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q. Accordingly, Management believes that the financial statement contained elsewhere in this Report present fairly in all material respects our financial position, results of operations and cash flows for the period presented.

 ****

***Changes in Internal Control over Financial Reporting***

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, during the period ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Part II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

We are not party to any material legal proceedings. We have in the past, and from time to time may be in the future, involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

**Item 1A. Risk Factors**

 

Risk factors that may affect our business and financial results are discussed within Item 1A "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 25, 2026, and our subsequent filings with the SEC.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

&nbsp;&nbsp;&nbsp;&nbsp;**(a)** **Recent Sales of Unregistered Equity Securities** 

On March 25, 2026, we entered into a securities purchase agreement with the accredited investors named in the signature pages thereto for a private investment in public equity financing (the "PIPE"), which closed on March 27, 2026, resulting in gross proceeds to us of $7.0 million, before deducting placement agent fees and offering expenses. In connection with the closing of the PIPE, and in reliance upon the exemption from registration requirements of Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder, we issued an aggregate of 5,600,000 shares of Class A Common Stock at a purchase price of $1.25 per share. We received net proceeds of $6,381,000 after deducting placement agent fees and escrow agent fees of $619,000, and intend to use the net proceeds from the PIPE for sales distribution expansion, technology development, and general corporate purposes.

&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Use of Proceeds** 

None.

&nbsp;&nbsp;&nbsp;&nbsp;**(c)** **Issuer Purchases of Equity Securities** 

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

Not applicable.

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit <br> Number** | **Description of Document** |
| 3.1(1) | [Second Amended and Restated Articles of Incorporation of Health In Tech, Inc.](https://www.sec.gov/Archives/edgar/data/2019505/000121390025024561/ea023425901ex3-1_health.htm) |
| 3.2(2) | [Third Amended and Restated Bylaws of Health In Tech, Inc.](https://www.sec.gov/Archives/edgar/data/2019505/000121390025018173/ea023246901ex3-1_health.htm) |
| 31.1\* | [Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea029067201ex31-1.htm) |
| 31.2\* | [Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea029067201ex31-2.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea029067201ex32-1.htm) |
| 32.2\*\* | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea029067201ex32-2.htm) |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

\* Filed herewith.

\*\* Exhibits 32.1 and 32.2 are being furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

(1) Filed as an exhibit to the registrant's Annual Report on Form 10-K filed with the SEC on March 17, 2025.

(2) Filed as an exhibit to the registrant's Current Report on Form 8-K filed with the SEC on February 27, 2025.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
|  | **Health In Tech, Inc.** | **Health In Tech, Inc.** |
| Date: May 14, 2026 | By: | /s/ Tim Johnson |
|  |  | Tim Johnson |
|  |  | **Chief Executive Officer (Principal Executive Officer)** |
| Date: May 14, 2026 | By: | /s/ LinLin Qian |
|  |  | LinLin Qian |
|  |  | **Chief Financial Officer (Principal Financial and Accounting Officer)** |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER<br> PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,<br> AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Tim Johnson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Health
In Tech, Inc.;

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;b) [Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986
and 33-8392/334-49313]; and

&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the
audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2026

---

| |
|:---|
| */s/ Tim Johnson* |
| Tim Johnson |
| Chief Executive Officer and Director |
| (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER<br> PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934<br> AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Julia (LinLin) Qian, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Health
In Tech, Inc.,

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;b) [Paragraph omitted
pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/334-49313] ; and

&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the
audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2026

 

---

| |
|:---|
| */s/ Julia (LinLin) Qian* |
| Julia (LinLin) Qian |
| Chief Financial Officer and Director |
| (Principal Financial and Accounting Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO<br> 18 U.S.C. SECTION 1350,<br> AS ADOPTED PURSUANT TO<br> SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Health In Tech, Inc. (the "Company") for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operation of the Company.

Date: May 14, 2026

 

---

| |
|:---|
| */s/ Tim Johnson* |
| Tim Johnson |
| Chief Executive Officer and Director |
| (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO<br> 18 U.S.C. SECTION 1350,<br> AS ADOPTED PURSUANT TO<br> SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Health In Tech, Inc. (the "Company") for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operation of the Company.

Date: May 14, 2026

 

---

| |
|:---|
| */s/ Julia (LinLin) Qian* |
| Julia (LinLin) Qian |
| Chief Financial Officer and Director |
| (Principal Financial and Accounting Officer) |

---